Aggrego Pulse - 4/13/23

Recommended

Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients With Multiple Myeloma

Janssen Presents First-ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Trial of KN046, a Novel Bispecific Antibody Targeting PD-L1 and CTLA-4 in Patients With Advanced Solid Tumors

HD201 Comparable to Referent Trastuzumab for HER2-Positive Breast Cancer

Preclinical Characterization and Phase 1 Trial Results of INBRX-109, a Third-generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

IMscin001 Part 2: A Randomised Phase 3, Open-label, Multicentre Study Examining the Pharmacokinetics, Efficacy, Immunogenicity, and Safety of Atezolizumab Subcutaneous versus Intravenous in Previously Treated Locally Advanced or Metastatic NSCLC

Menstrual Suppression in the Myelosuppressed: A Retrospective Cohort Study

Camrelizumab Plus Apatinib and Temozolomide as First-line Treatment in Patients With Advanced Acral Melanoma

Aggrego Pulse - 4/13/23

header-info

Apr, 11, 2023

On this week's episode of Aggrego Pulse, Dr Brian Van Tine, Phase 1 Director at Washington University in St. Louis, shares updates in myeloproliferative neoplasms, liver cancer, and cervical cancer.